Summary Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated. There were five early deaths due to disease progression. (Slotman & Rao, 1988) .
Despite the high response rates achieved with either single agent platinum chemotherapy or platinum based combination chemotherapy in women with advanced epithelial ovarian cancer, long term survival in this disease remains poor with the majority of patients ultimately relapsing and dying of their disease (Wharton et al., 1984) . Thus there is a need to improve chemotherapy for both initial therapy and for relapsed ovarian cancer. Furthermore there is the need to identify novel therapies for patients with a low probability of responding to conventional cytotoxic chemotherapy (Blackledge et al., 1989) .
Several studies have demonstrated the presence of both sex steroid hormone receptors and gonadotrophin releasing hormone (GnRHs) receptors in epithelial ovarian tumour cells. It has been demonstrated that 50% of epithelial ovarian cancers are positive for oestrogen receptors, whilst 53% are progesterone receptor positive and 88% are androgen receptor positive (Rao et al., 1990 (Slotman & Rao, 1988) .
Goserelin (Zoladex) is a synthetic long acting lutenising hormone releasing hormone (LHRH) agonist which has been shown to cause tumour shrinkage in premenopausal women with breast carcinoma (Williams et al., 1986) and to a lesser extent in postmenopausal women (Harris et al., 1989) . This agent has been shown to suppress circulating levels of lutenising hormone, follicle stimulating hormone, testosterone, androstenedione and oestradiol in postmenopausal women receiving the drug by monthly depot subcutaneous (sc) injections (Dowsett et al., 1988) . Whilst this may not be relevant in oophorectomised women, it has been shown that women with epithelial ovarian cancer have higher levels of oestradiol than postmenopausal controls (Mahlck et al., 1988 
Patients and methods
Women with histologically proven epithelial ovarian cancer who had relapsed following at least one trial of chemotherapy or who were considered too ill to receive chemotherapy for their disease were studied. There was no upper age limit. The details of these patients are shown in (WHO, 1979) . Survival was defined as the period from diagnosis to death and response duration as the interval from response to disease progression.
Results
Patients received a median of two cycles (range, 1-11) of goserelin. There were no complete responders but two (6.7%) patients achieved a partial remission lasting 40 and 105 weeks respectively. One patient with a poorly differentiated serous cystadenocarcinoma with an enlarged supraclavicular node and involved paraaortic nodes had progressed after three courses of carboplatin and subsequently responded to treatment with goserelin. The second responder who also had a poorly differentiated serous cystadenocarcinoma had Correspondence: B.M.J. Cantwell. M.J. LIND et al. witnessed.
Discussion
The fact that ovarian tumours possess sex hormone receptors has meant that endocrine therapy for recurrent disease has been regarded as an attractive alternative to conventional cytotoxic chemotherapy. Most efforts at endocrine therapy in epithelial ovarian cancer have concentrated on the use of either progestagens or the antioestrogen tamoxifen. Several progestagens have been used including 17-a-hydroxyprogesterone, 1 7-a-hydroxy-1 9-norprogesterone-1 7-n-caproate, 6, 1 7-a-dimethyl-6-dehydroprogesterone, medroxyprogesterone acetate, and megesterol acetate. Unfortunately response rates with these agents have been disappointingly low ranging from 10-15% (Slotman & Rao, 1988) . The other most widely used hormonal agent in the treatment of epithelial ovarian cancer has been the antioestrogen tamoxifen which has produced objective response rates from 0-10% (Slotman & Rao, 1988) . Despite the expression of oestrogen receptors in a sizable proportion of human ovarian carcinomas, and a positive relationship between tumour volume and plasma oestradiol levels (Mahlck et al., 1988) Our phase II study of goserelin in advanced epithelial ovarian cancer was the first to use goserelin. Our objective response rate was only 6.7% (2/30) but most patients had very advanced cancers and were heavily pre-treated. Further more we included two patients with borderline malignancies (pseudomyxoma peritoneii) whom are generally refractory to most cytotoxic or endocrine therapies. Overall seven (23%) patients had absence of disease progression for 6 months or more. In advanced breast cancer absence of disease progression i.e. disease stabilisation for 5 months or more following therapy confers the same survival benefit as partial response to therapy (Howell et al., 1988) . Thus the disease stabilisation seen in our patients may confer some survival advantage. LHRH agonists should be evaluated earlier in the management of women with epithelial ovarian cancer, perhaps at first relapse or in patients resistant to first line conventional cytotoxic chemotherapy.
If our results are validated, then future studies could address the combination of goserelin with antiandrogens which might provide better growth inhibition, targeting both putative autocrine loop elements (LHRH receptors) and an androgen mediated endocrine drive. Androgens may be of greater importance in epithelial ovarian cancer than oestrogens since as many as 88% of these tumours were found to express androgen receptors (Rao et al., 1990) .
